These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 36640805)
1. Therapeutic Drug Monitoring Can Guide the Intravenous-to-Subcutaneous Switch of Infliximab and Vedolizumab: A Simulation Study. Wang Z; Verstockt B; Sabino J; Ferrante M; Vermeire S; Dreesen E Clin Gastroenterol Hepatol; 2023 Nov; 21(12):3188-3190.e2. PubMed ID: 36640805 [No Abstract] [Full Text] [Related]
2. Biologic Therapeutic Drug Monitoring in Australia. J Connor S J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():8-9. PubMed ID: 26990573 [No Abstract] [Full Text] [Related]
3. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. Scott FI; Luo M; Shah Y; Lasch K; Vajravelu RK; Mamtani R; Fennimore B; Gerich ME; Lewis JD J Crohns Colitis; 2020 Jun; 14(5):575-587. PubMed ID: 31901085 [TBL] [Abstract][Full Text] [Related]
4. Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). Peyrin-Biroulet L; Loftus EV; Colombel JF; Danese S; Rogers R; Bornstein JD; Chen J; Schreiber S; Sands BE; Lirio RA Gastroenterology; 2021 Oct; 161(4):1156-1167.e3. PubMed ID: 34144047 [TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study. Hupé M; Rivière P; Nancey S; Roblin X; Altwegg R; Filippi J; Fumery M; Bouguen G; Peyrin-Biroulet L; Bourreille A; Caillo L; Simon M; Goutorbe F; Laharie D Aliment Pharmacol Ther; 2020 May; 51(9):852-860. PubMed ID: 32201971 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Wilson MR; Bergman A; Chevrou-Severac H; Selby R; Smyth M; Kerrigan MC Eur J Health Econ; 2018 Mar; 19(2):229-240. PubMed ID: 28271250 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis. Schultz BG; Diakite I; Carter JA; Snedecor SJ; Turpin R J Manag Care Spec Pharm; 2021 Nov; 27(11):1592-1600. PubMed ID: 34714104 [No Abstract] [Full Text] [Related]
10. Letter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-it depends on how you use the drug. Con D; Srinivasan A Aliment Pharmacol Ther; 2024 Jan; 59(1):140-141. PubMed ID: 38085945 [No Abstract] [Full Text] [Related]
11. Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience. Verstockt B; Claeys C; De Hertogh G; Van Assche G; Wolthuis A; D'Hoore A; Vermeire S; Ferrante M United European Gastroenterol J; 2019 Nov; 7(9):1215-1225. PubMed ID: 31700634 [TBL] [Abstract][Full Text] [Related]
12. The impact of biological interventions for ulcerative colitis on health-related quality of life. LeBlanc K; Mosli MH; Parker CE; MacDonald JK Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain. Trigo-Vicente C; Gimeno-Ballester V; Montoiro-Allué R; López-Del Val A Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):321-329. PubMed ID: 29192530 [TBL] [Abstract][Full Text] [Related]
14. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis. Jairath V; Chan K; Lasch K; Keeping S; Agboton C; Blake A; Patel H Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):711-722. PubMed ID: 33599181 [No Abstract] [Full Text] [Related]
15. Positioning Infliximab and Vedolizumab in the Treatment of Moderate-to-Severe Ulcerative Colitis. Sheehan JL; Cohen-Mekelburg S Gastroenterology; 2022 May; 162(6):1764-1765. PubMed ID: 34864070 [No Abstract] [Full Text] [Related]
16. Special considerations for biologic medications in pediatric ulcerative colitis. Jerger L; Hyams JS Expert Opin Biol Ther; 2020 Apr; 20(4):429-435. PubMed ID: 31652087 [No Abstract] [Full Text] [Related]
17. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Flanagan E; Gibson PR; Wright EK; Moore GT; Sparrow MP; Connell W; Kamm MA; Begun J; Christensen B; De Cruz P; Shelton E; Dowling D; Andrews JM; Brown SJ; Niewiadomski O; Ward MG; Rosella O; Rosella G; Kiburg KV; Ross AL; Bell SJ; Aliment Pharmacol Ther; 2020 Nov; 52(10):1551-1562. PubMed ID: 32981127 [TBL] [Abstract][Full Text] [Related]
18. The biologics of ulcerative colitis. Macaluso FS; Renna S; Orlando A; Cottone M Expert Opin Biol Ther; 2017 Feb; 17(2):175-184. PubMed ID: 27960557 [TBL] [Abstract][Full Text] [Related]